Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings Article Swipe

View

Related Concepts

Maraviroc Pharmacokinetics Vaginal ring Medicine Placebo Pharmacodynamics Microbicide Vaginal microbicide Pharmacology Adverse effect Urology Internal medicine Population Microbicides for sexually transmitted diseases Human immunodeficiency virus (HIV) Pathology Virology Family planning Research methodology Health services Environmental health Alternative medicine

Beatrice A. Chen , Lori Panther , Mark A. Marzinke , Craig W. Hendrix , Craig Hoesley , Ariane van der Straten , Marla Husnik , Lydia Soto‐Torres , Annaléne Nel , Sherri Johnson , Nicola Richardson‐Harman , Lorna K. Rabe , Charlene S. Dezzutti ·

YOU? · · 2015 · Open Access · · DOI: https://doi.org/10.1097/qai.0000000000000702 · OA: W645608458

In this first study of a combination microbicide vaginal ring, all 4 rings were safe and well tolerated. Tissue DPV concentrations were 1000 times greater than plasma concentrations and single drug rings had more stable pharmacokinetics. DPV, but not MVC, demonstrated concentration-dependent inhibition of HIV-1 infection in cervical tissue. Because MVC concentrations were consistently detectable only in CVF and not in plasma, improved drug release of MVC rings is needed.